Cabozantinib as salvage therapy for radioiodine-refractory DTC who progressed after treatment with VEGFR targeted therapy also increased the objective response rate by 15% and prolonged PFS, indicating the potential of cabozantinib as a treatment option for thyroid cancer patients with no available standard of care.507,508 Therefore, cabozantinib was soon approved as a second-line treatment for adult and pediatric patients with LA- or metastatic DTC who are ineligible or refractory to radioactive iodine. Here, KDR is linked to thyroid cancer.